Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients
暂无分享,去创建一个
J. de la Rubia | E. Such | G. Sanz | A. Sempere | I. Jarque | S. Romero | Carmen Mas-Ochoa | L. Senent | R. Andreu | M. Ibáñez | Alessandro Liquori | Gayane Avestisyan | A. Vicente | María José Macián | M. Melendez | Mireya Morote-Faubel | Pedro Asensi | María Pilar Lloret | I. Picón | A. Pacios | E. Donato | Carmen M Alonso | C. Cañigral | M. Santiago | Irene Luna | A. Liquori | P. Asensi | I. Luna
[1] F. Solé,et al. A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms , 2021, Cancers.
[2] M. Hernández-Sánchez,et al. From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct , 2021, Cancers.
[3] A. Wiestner. Validating genomic tools for precision medicine in CLL: ERIC leads the way , 2021, Haematologica.
[4] M. Tormo,et al. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project , 2020, Haematologica.
[5] Rajesh R Singh,et al. Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances and Applications. , 2020, The Journal of molecular diagnostics : JMD.
[6] E. Campo,et al. Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study , 2020, Haematologica.
[7] G. Gaidano,et al. Precision Medicine Management of Chronic Lymphocytic Leukemia , 2020, Cancers.
[8] Benjamin L. Ebert,et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2019, Nature Medicine.
[9] J. Cigudosa,et al. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2019, British journal of haematology.
[10] I. Zalcberg,et al. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations , 2019, Hematology, transfusion and cell therapy.
[11] F. Bosch,et al. Chronic lymphocytic leukaemia: from genetics to treatment , 2019, Nature Reviews Clinical Oncology.
[12] R. Foà,et al. Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia , 2019, Haematologica.
[13] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.
[14] L. Lopez,et al. Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia , 2017, Leukemia.
[15] A. López-Guillermo,et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.
[16] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[17] A. Valencia,et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.
[18] E. Campo,et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.
[19] M. Hallek,et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.